11:03 AM EDT, 06/10/2025 (MT Newswires) -- Jazz Pharmaceuticals ( JAZZ ) said Tuesday that the supplemental new drug application for Zepzelca plus Tecentriq as a first-line maintenance treatment of extensive-stage small cell lung cancer has been accepted by the US Food and Drug Administration for priority review.

The Prescription Drug User Fee Act action date is Oct. 7, the company said.

The supplemental new drug application is based on a phase 3 study that showed that the combination improved progression-free survival and overall survival compared with Tecentriq alone, according to the company.

Price: 113.18, Change: +1.31, Percent Change: +1.17